Increased clopidogrel response is associated with ABCC3 expression: A pilot study

Clinica Chimica Acta

Volumn 413, Issue 3-4, 2012, Pages 417-421

  Luchessi, André Ducati ^a   Silbiger, Vivian Nogueira ^b   Cerda, Alvaro ^a   Hirata, Rosario Dominguez Crespo ^a   Carracedo, Angel ^c   Brion, Maria ^c,d   Iñiguez, Andres ^e   Bravo, Marisol ^e   Bastos, Guillermo ^e   Sousa, Amanda Guerra Morais Rego ^f   Hirata, Mario Hiroyuki ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DO MEIXOEIRO   (Spain)

^f INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

ABCB1; ABCC3; Antiplatelet agents; Clopidogrel; Pharmacogenomics

Indexed keywords

ABC TRANSPORTER C3; CARRIER PROTEINS AND BINDING PROTEINS; CLOPIDOGREL; MEMBRANE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC3 GENE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG RESPONSE; GAPD GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PILOT PROJECTS; RNA, MESSENGER; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84355162808     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.10.018     Document Type: Article

References (27)

1. Taubert D., Kastrati A., Harlfinger S., Gorchakova O., Lazar A., von Beckerath N., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004, 92(2):311-316.
2. Sangkuhl K., Klein T.E., Altman R.B. Clopidogrel pathway. Pharmacogenet Genomics 2010, 20(7):463-465.
3. Hankey G.J., Eikelboom J.W. Aspirin resistance. Lancet 2006, 367(9510):606-617.
4. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113(19):2363-2372.
5. Gladding P., Webster M., Ormiston J., Olsen S., White H. Antiplatelet drug nonresponsiveness. Am Heart J 2008, 155(4):591-599.
6. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109(25):3171-3175.
7. Taubert D., von Beckerath N., Grimberg G., Lazar A., Jung N., Goeser T., et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006, 80(5):486-501.
8. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(21):2250-2251.
9. Feher G., Feher a, Pusch G., Lupkovics G., Szapary L., Papp E. The genetics of antiplatelet drug resistance. Clin Genet 2009, 75(1):1-18.
10. Lee C.a, Cook J.a, Reyner E.L., Smith D.a P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010, 6(5):603-619.
11. Oostendorp R.L., Beijnen J.H., Schellens J.H.M. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 2009, 35(2):137-147.
12. Rebecchi I.M.M., Rodrigues A.C., Arazi S.S., Genvigir F.D.V., Willrich M.A.V., Hirata M.H., et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 2009, 77(1):66-75.
13. Ieiri I., Takane H., Hirota T., Otsubo K., Higuchi S. Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. Expert Opin Drug Metab Toxicol 2006, 2(5):651-674.
14. Kock K., Grube M., Jedlitschky G., Oevermann L., Siegmund W., Ritter C.A., et al. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy. Clin Pharmacokinet 2007, 46(6):449-470.
15. Gradhand U., Tegude H., Burk O., Eichelbaum M., Fromm M.F., Kónig J. Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene. Life Sci 2007, 80(16):1490-1494.
16. Niessen J., Jedlitschky G., Grube M., Kawakami H., Kamiie J., Ohtsuki S., et al. Expression of ABC-type transport proteins in human platelets. Pharmacogenet Genomics 2010, 20(6):396-400.
17. Máller P.J., Dally H., Klappenecker C.N., Edler L., Jáger B., Gerst M., et al. Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 2009, 124(7):1669-1674.
18. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(9):16-21.
19. Kones R. Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag 2010 Jan, 6:635-656.
20. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Outcome. J Am Coll Cardiol 2008, 52(14):1128-1133.
21. Cuisset T., Frere C., Poyet R., Quilici J., Gaborit B., Bali L., et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010, 103(1):39-45.
22. Angiolillo D.J., Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best practice & research. Clin Endocrinol Metab 2009 Jun, 23(3):375-388.
23. Bohan A., Chen W.-S., Denson L.a, Held M.a, Boyer J.L. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J Biol Chem 2003, 278(38):36688-36698.
24. Lu H., Gonzalez F.J., Klaassen C. Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha. Toxicol Sci 2010, 118(2):380-390.
25. Rodrigues A.C., Curi R., Britto L.R.G., Rebbechi I.M.M., Hirata M.H., Bertolami M.C., et al. Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. Biochim Biophys Acta 2006, 1760(12):1866-1873.
26. Waehre T., Damås J.K., Pedersen T.M., Gullestad L., Yndestad a, Andreassen a K., et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006, 4(10):2140-2147.
27. Arazi S.S., Genvigir F.D.V., Willrich M.A.V., Hirata M.H., Dorea E.L., Bernik M., et al. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin Chim Acta 2008, 393(2):119-124.